In the recent news, pharmaceutical giant
Johnson & Johnson (JNJ) has been in the spotlight for various reasons- both positive and negative. On one hand, the company is reportedly in talks to acquire
Protagonist Therapeutics, causing Protagonist's stock to surge significantly. Along with this, JNJ's stock has also been showing
promising signs of reaching higher highs in the fourth quarter. Financial analysts predict a positive Q3 earnings report and a stronger position for the company. However, the company has also been ordered to pay $966 million as part of a
talc cancer case, putting a significant financial burden on their shoulders. Other advancements include FDA approval for
INLEXZO™ (gemcitabine intravesical system) that aims to revolutionize the treatment of certain bladder cancers. Finally, Johnson & Johnson has added another feather in its cap by being named in Fortune’s 2025 America’s Most Innovative Companies list.
Johnson Johnson JNJ News Analytics from Tue, 10 Dec 2024 13:10:08 GMT to Sat, 11 Oct 2025 21:45:24 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor -4
